drug pricing

Politics Rachel Cohrs

Stéphane Bancel, Bernie Sanders spar over what Moderna owes the federal government

Pharmalot Ed Silverman

STAT Plus: NIH rejects bid to cut a cancer drug’s price by sidestepping patents

Pharmalot Ed Silverman

STAT Plus: Sanofi becomes the third leading insulin maker to lower list prices, cutting Lantus price by 78%

Pharmalot Ed Silverman

STAT Plus: Here’s why there aren’t many cheap, generic versions of pricey inhalers

Politics John Wilkerson

STAT Plus: Medicare chief on the new drug price negotiation program’s operations, hiring, and timelines

Health Nicholas Florko and Lizzy Lawrence

STAT Plus: Science adviser Collins hints at a big White House ask to eliminate hepatitis C

Politics Rachel Cohrs

STAT Plus: Biden proposes expanding Medicare drug negotiation program

Politics John Wilkerson

STAT Plus: By cutting insulin prices, Eli Lilly avoids paying big Medicaid rebates

Insurance Tara Bannow

Same patient, same drug, same insurer — coverage denied

Pharmalot Ed Silverman

STAT Plus: U.S. trade rep urged not to sanction countries if they sidestep patents on Vertex cystic fibrosis drugs

Pharmalot Ed Silverman

STAT Plus: Canadian drug price board member resigns over government failure ‘to support real change’

Pharmalot Ed Silverman

STAT Plus: Lawmakers urge U.S. patent office to scrutinize Merck over ‘abuse’ of the system

Pharmalot Ed Silverman

STAT Plus: Dutch group sues AbbVie for human rights violations stemming from Humira pricing

Pharmalot Ed Silverman

‘Caught in the middle’: A battle between Vertex and insurers is leaving cystic fibrosis patients with crushing drug costs

Pharmalot Ed Silverman

STAT Plus: French court hands Novartis and Roche another win in battle over antitrust allegations involving eye drug

First Opinion David Mitchell

STAT Plus: Another pharma industry flip-flop: Claims about the IRA’s effect on small-molecule versus biologic drugs

Politics Rachel Cohrs and John Wilkerson

STAT Plus: Biden administration pitches 3 big new drug pricing reform experiments

Politics Rachel Cohrs

STAT Plus: Medicare advisers suggest tweaks to coverage process for Alzheimer’s drugs

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Generic drugmakers may be helped by Inflation Reduction Act; Bayer union warns not to split the company

Politics John Wilkerson

STAT Plus: Generics companies fought to stop the new drug pricing law. But they may end up benefiting

Politics Rachel Cohrs

STAT Plus: Medicare details forthcoming penalties for drug price hikes

First Opinion MacKay Jimeson

State of the Union highlights America’s awkward conversation on financing the development of new medicines

Politics John Wilkerson

STAT Plus: Senate panel passes drug patent reforms, but not without dissent

Politics Sarah Owermohle and John Wilkerson

STAT Plus: In State of the Union, Biden pitches addiction, mental health care policies as opportunities for bipartisanship

Biotech Rachel Cohrs

STAT Plus: How one biotech investor is changing his calculus now that Medicare can negotiate drug prices